Immunocore’s Kimmtrak Anchors Growth as Pipeline Eyes Bigger Markets
Immunocore’s Kimmtrak hit ~$400M in 2025 sales with strong 2026 momentum. Solid cash, advancing Phase 3 trials, and Wall Street Buy ratings signal further upside.
NOTRELOAD AI
What Makes Nuvation Bio a “Low-Risk, High-Reward” Stock According to Cantor
Cantor Fitzgerald starts coverage of Nuvation Bio at Overweight, citing a low-risk oncology story with upside from Ibtrozi and safusidenib.
Broadcom Eyes $60B–$100B Debt Raise for AI Infrastructure, Backed by Blackstone and Apollo
BMO Capital starts Broadcom coverage with Outperform and $455 price target, highlighting its AI chip leadership, custom ASICs, and strong margins.
O-I Glass Stock: Citi Moves to Buy, Flags Near-Term Catalysts
Citi upgrades O-I Glass to Buy, citing trough valuation levels, a derisked 2026 outlook, and the stock being meaningfully oversold.
Ross Stores Raises Full-Year Outlook as Shopper Traffic and Spending Surge
Ross Stores raised its full-year earnings outlook after stronger demand from new and existing customers drove 10% same-store sales growth in Q2.
Roth Capital Reiterates Buy Rating and $20 Target on CELZ as ADAPT Trial Completes Enrollment
CELZ-201 (Olastrocel) ADAPT trial fully enrolled and treated, including opioid patients. Clean safety profile and meaningful pain relief at 180 days; advancing toward RMAT review.